Información del artículo
La gastroenteritis por rotavirus es la principal causa de diarrea en los lactantes. En la Unión Europea, con una población estimada de 23,6 millones de niños menores de 5 años, se calcula que anualmente ocurren aproximadamente 3,6 millones de episodios de gastroenteritis por rotavirus, se producen 231 muertes, 87.000 hospitalizaciones y alrededor de 700.000 visitas médicas. Los rotavirus del grupo A son la causa más frecuente de diarrea aguda grave en los niños menores de 2 años de edad, por lo que el desarrollo en la investigación de vacunas se ha dirigido hacia este serogrupo. Con este fin se han desarrollado cepas vacunales resortantes multivalentes, obtenidas a partir de la reordenación genética en el laboratorio de cepas de rotavirus de origen animal (simio, bovino) con cepas de rotavirus de origen humano. Igualmente, en los últimos años se ha conseguido el desarrollo de cepas vacunales de rotavirus de origen humano exclusivamente. Tras la retirada del mercado americano en 1999 de la vacuna resortante de rotavirus simio-humano (RotaShieldTM) por su asociación con un ligero incremento de invaginación intestinal en vacunados, en 2006 se comercializan en Europa, tras importantes ensayos clínicos de eficacia y seguridad, 2 nuevas vacunas antirrotavirus orales: una vacuna monovalente de rotavirus de origen humano (Rotarix®) y otra vacuna pentavalente resortante bovina-humana (RotaTeq®). La incorporación de estas nuevas vacunas, seguras y eficaces, en los programas vacunales permitirá reducir en el ámbito mundial la gran morbilidad de esta enfermedad y combatir de manera eficaz la importante mortalidad que presenta en los países en vías de desarrollo.
Palabras clave:
Rotavirus
Gastroenteritis aguda
Vacunas antirrotavirus
RotaShield™
Rotarix®
Rotateq®
Rotavirus gastroenteritis is the main cause of diarrhea in infants. In the European Union, with an estimated population of 23.6 million children aged less than 5 years old, there are approximately 3.6 million episodes of rotavirus gastroenteritis each year, leading to 231 deaths, 87,000 hospitalizations, and approximately 700,000 medical consultations. Group A rotaviruses are the most frequent cause of severe acute diarrhea in children aged less than 2 years old, and consequently research into the development of vaccines has been directed at this serogroup. To do this, multivalent reassortant vaccine strains have been developed, obtained from gene rearrangement in the laboratory of animal rotavirus strains (rhesus, bovine) with human rotavirus strains. Equally, in the last few years, exclusively human rotavirus vaccine strains have been developed. After the withdrawal of the rhesus-human reassortant rotavirus vaccine (RotaShieldTM) from the American market in 1999, due to its association with a slight increase of intussusception in vaccinated individuals, in 2006, two new oral rotavirus vaccines were commercialized in Europe after clinical trials of their efficacy and safety: a monovalent human rotavirus vaccine (Rotarix®) and a pentavalent reassortant bovine-human vaccine (RotaTeq®). The incorporation of these new safe and effective vaccines in vaccination schedules will reduce the substantial morbidity of this disease worldwide and will effectively combat the marked mortality caused by rotavirus in developing countries.
Key words:
Rotavirus
Acute gastroenteritis
Rotavirus vaccine
RotaShield™
Rotarix®
Rotateq®
El Texto completo está disponible en PDF
Bibliografía
[1.]
A.Z. Kapikian, R.M. Chanock.
Rotaviruses.
Field's virology, pp. 1657-1708
[2.]
U.D. Parashar, C.H. Gibson, J.S. Bresee, R.I. Glass.
Rotavirus and severe childhood diarrhea.
Emerg Infect Dis, 12 (2006), pp. 304-306
[3.]
M. Soriano-Gabarró, J. Mrukowicz, T. Vesikari, T. Verstraeten.
Burden of rotavirus disease in European Union countries.
Pediatr Infect Dis J, 25 (2006), pp. 7S-11S
[4.]
The Pediatric ROTavirus European CommitTee (PROTECT).
The paediatric burden of rotavirus disease in Europe.
Epidemiol Infect, 44 (2006), pp. 1-9
[5.]
P. Van Damme, C. Giaquinto, F. Huet, L. Gothefors, M. Maxwell, M. Van der Wielen, Por el REVEAL Study Group.
Multicenter prospective study of the burden of rotavirus acute gastroenteritis in Europe, 2004-2005: The REVEAL Study.
J Infect Dis, 195 (2007), pp. 4S-16S
[6.]
U.D. Parashar, E.G. Hummelman, J.S. Bresee, M.A. Miller, R.I. Glass.
Global illness and deaths caused by rotavirus disease in children.
Emerg Infect Dis, 9 (2003), pp. 565-572
[7.]
S. Calderón.
Incidencia de diarreas en una cohorte de niños en la ciudad de Sevilla.
An Esp Pediatr, 32 (1990), pp. 114-118
[8.]
A.C. Velasco, M.L. Mateos, G. Mas, A. Pedraza, M. Díez, A. Gutiérrez.
Three-year prospective study of intestinal pathogens in Madrid, Spain.
J Clin Microbiol, 20 (1984), pp. 290-292
[9.]
I. Wilhelmi, C. Mier, E. Román, J. Colomina, J. Prat, A. Sánchez-Fauquier.
The molecular epidemiology of the rotavirus in Spanish children. The Rotavirus Study Group (GER).
Enferm Infecc Microbiol Clin, 17 (1999), pp. 509-514
[10.]
L.E. Visser, P.R. Cano, N.J. Gay, J.F. Martínez Navarro.
Impact of rotavirus disease in Spain: an estimate of hospital admissions due to rotavirus.
Acta Paediatr, 88 (1999), pp. 72-76
[11.]
C.J. Rodríguez, B. Peñalver, M.C. Curros Novo, B.P. Pavon, A.C. Alonso, J.M. Fraga.
Rotavirus: clinical and epidemiological study in hospitalized children under two years of age.
An Esp Pediatr, 45 (1996), pp. 499-504
[12.]
G. Cilla, G.E. Pérez, L.D. Pineiro, A. Iturzaeta, D. Vicente.
Hospitalizations for rotavirus gastroenteritis in Gipuzkoa (Basque country), Spain.
Emerg Infect Dis, 5 (1999), pp. 834-835
[13.]
G. Cilla, E. Pérez, M.C. López, A. Gilsetas, M. Gomariz.
Incidence, seasonality and serotypes of rotavirus in Gipuzkoa (Basque country), Spain. A 14-year study.
Epidemiol Infect, 125 (2000), pp. 677-683
[14.]
A. Gil de Miguel, P. Carrasco, J. Esteban, M. San Martín, A. González.
Ingresos hospitalarios atribuibles a rotavirus en niños de la Comunidad de Madrid, período 1999-2000.
An Pediatr (Barc), 64 (2006), pp. 530-535
[15.]
P. Van Damme, C. Giaquinto, M. Maxwell, P. Todd, M. Van der Wielen, Por el REVEAL Study Group.
Distribution of Rotavirus Genotypes in Europe, 2004-2005: The REVEAL Study.
J Infect Dis, 195 (2007), pp. 17S-25S
[16.]
A. Sánchez-Fauquier, V. Montero, S. Moreno, M. Solé, J. Colomina, M. Iturriza-Gomara, et al.
Human rotavirus G9 and G3 as major cause of diarrhea in hospitalized children, Spain.
Emerg Infect Dis, 12 (2006), pp. 1536-1541
[17.]
E. Román.
Vacunación frente a rotavirus.
Bol Pediatr, 46 (2006), pp. 185-191
[18.]
R.I. Glass, U.D. Parashar, J.S. Bresee, R. Turcios, T.K. Fischer, M.A. Widdowson, et al.
Rotavirus vaccines: current prospects and future challenges.
Lancet, 368 (2006), pp. 323-332
[19.]
J.P. Buttery, C. Kirkwood.
Rotavirus vaccines in developed countries.
Curr Opin Infect Dis, 20 (2007), pp. 253-258
[20.]
M.E. Conner, C.D. Zarley, B. Hu, S. Parsons, D. Drabinski, S. Greiner, et al.
Viruslike particles as a rotavirus subunit vaccine.
J Infect Dis, 174 (1996), pp. 88S-92S
[21.]
M. Ciarlet, S.E. Crawford, C. Barone, et al.
Subunit rotavirus vaccine administered parenterally to rabbits induces active protective immunity.
J Virol, 72 (1998), pp. 9233-9246
[22.]
B. Jiang, M.K. Estes, C. Barone, et al.
Heterotypic protection from rotavirus infection in mice vaccinated with virus-like particles.
Vaccine, 17 (1999), pp. 1005-1013
[23.]
J.E. Herrmann, S.C. Chen, E.F. Fynan, J.C. Santoro, H.B. Greenberg, S. Wang, et al.
Protection against rotavirus infections by DNA vaccination.
J Infect Dis, 174 (1996), pp. 93S-97S
[24.]
K. Yang, S.H. Wang, K.O. Chang, S.H. Lu, L.J. Saif, H.B. Greenberg, et al.
Immune responses and protection obtained with rotavirus VP6 DNA vaccines given by intramuscular injection.
Vaccine, 19 (2001), pp. 3285-3291
[25.]
S.E. Coffin, M. Klinek, P.A. Offit.
Induction of virus-specifi c antibody production by lamina propria lymphocytes following intramuscular inoculation with rotavirus.
J Infect Dis, 172 (1995), pp. 874-878
[26.]
M.E. Conner, S.E. Crawford, C. Barone, M.K. Estes.
Rotavirus vaccine administered parenterally induces protective immunity.
J Virol, 67 (1993), pp. 6633-6641
[27.]
D.I. Bernstein, R.I. Glass, G. Rodgers, B.L. Davidson, D.A. Sack, Por el US Rotavirus Vaccine Efficacy Group.
Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children.
JAMA, 273 (1995), pp. 1191-1196
[28.]
M.B. Rennels, R.I. Glass, P.H. Dennehy, D.I. Bernstein, M.E. Pichichero, E.T. Zito, et al.
Safety and efficacy of high dose rhesus-human reassortant rotavirus vaccines. Report of the National Multicenter Trial.
Pediatrics, 97 (1996), pp. 7-13
[29.]
A.Z. Kapikian, Y. Hoshino, R.M. Chanock, Y. Pérez-Schael.
Efficacy of a quadrivalent rhesus rotavirus-based human rotavirus vaccine aimed at preventing severe rotavirus diarrhea in infants and young children.
J Infect Dis, 174 (1996), pp. 65S-72S
[30.]
I. Pérez-Schael, M.J. Guntinas, M. Pérez, V. Pagone, A.M. Rojas, R. González, et al.
Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela.
N Engl J Med, 337 (1997), pp. 1181-1187
[31.]
M. Santosham, L.H. Moulton, R. Reid, J. Croll, R. Weatherholt, R. Ward, et al.
Efficacy and safety of highdose rhesus-human reassortant rotavirus vaccine in Native American populations.
J Pediatr, 131 (1997), pp. 632-638
[32.]
J. Joensuu, E. Koskenniemi, X.L. Pang, T. Vesikari.
Randomized placebo-controlled trial of rhesus human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis.
Lancet, 350 (1997), pp. 1205-1209
[33.]
M. Staat, M. Cortese, J. Bresee, R. Begue, C. Vitek, P. Rhodes, et al.
Rhesus rotavirus vaccine effectiveness and factors associated with receipt of vaccine.
Pediatr Infect Dis J, 25 (2006), pp. 1013-1018
[34.]
C.F. Lanata, K. Midthun, R.E. Black, B. Butron, A. Huapaya, M.E. Penny, et al.
Safety, immunogenicity and protective efficacy of one and three doses of the tetravalent rhesus rotavirus vaccine in infants in Lima, Perú.
J Infect Dis, 174 (1996), pp. 268-275
[35.]
A.C. Linhares, Y.B. Gabbay, J.D. Mascarenhas, R.B. De Freitas, C.S. Oliveira, N. Bellesi, et al.
Immunogenicity, safety and efficacy of tetravalent rhesus-human, reassortant rotavirus vaccine in Belem, Brazil.
Bull WHO, 74 (1996), pp. 491-500
[36.]
R. Dagan, I. Kassis, B. Sarov, K. Midthun, B.L. Davidson, T. Vesikari, et al.
Safety and immunogenicity of oral tetravalent human-rhesus reassortant rotavirus in neonates.
Pediatr Infect Dis J, 11 (1992), pp. 991-996
[37.]
P.H. Dennehy, G.C. Rodgers Jr, R.L. Ward, A.J. Markwick, M. Mark, E.T. Zito, Por el US Rhesus Rotavirus Vaccine Study Group.
Comparative evaluation of reactogenicity and immunogenicity of two dosages of oral tetravalent rhesus rotavirus vaccine.
Pediatr Infect Dis J, 15 (1996), pp. 1012-1018
[38.]
American Academy of Pediatrics, Committee on Infectious Diseases.
Prevention of Rotavirus disease: Guidelines for use of Rotavirus vaccine.
Pediatrics, 102 (1998), pp. 1483-1491
[39.]
Centers for Disease Control and Prevention.
Rotavirus vaccine for the prevention of rotavirus gastroenteritis among children: recommendations of the Advisory Committee on Immunization Practices (ACIP).
MMWR, 48 (1999), pp. 1-23
[40.]
Centers for Disease Control and Prevention.
Intussuception among recipients of rotavirus vaccine-United States 1998-1999.
MMWR, 48 (1999), pp. 577-581
[41.]
Centers for Disease Control and Prevention.
Withdrawal of rotavirus vaccine recommendation.
MMWR, 48 (1999), pp. 1007
[42.]
P. Kramarz, E.K. France, F. Destefano, S.B. Black, H. Shinefield, J.I. Ward, et al.
Population-based study of rotavirus vaccination and intussusception.
Pediatr Infect Dis J, 20 (2001), pp. 410-416
[43.]
T.V. Murphy, P.M. Gargiullo, M.S. Massoudi, D.B. Nelson, A.O. Jumaan, C.A. Okoro, et al.
Intussusception among infants given an oral rotavirus vaccine.
N Engl J Med, 344 (2001), pp. 564-572
[44.]
B.R. Murphy, D.M. Morens, L. Simonsen, R.M. Chanock, J.R. La Montagne, A.Z. Kapikian.
Reappraisal of the association of intussusception with the licensed live rotavirus vaccine challenges initial conclusions.
J Infect Dis, 187 (2003), pp. 1301-1308
[45.]
L.R. Zanardi, P. Haber, G.T. Mootrey, M.T. Niu, M. Wharton.
Intussusception among recipients of rotavirus vaccine: reports to the vaccine adverse event reporting system.
Pediatrics, 107 (2001), pp. 97E-102E
[46.]
L. Simonsen, C. Viboud, A. Elixhauser, et al.
More on RotaShield and intussusception: the role of age at the time of vaccination.
J Infect Dis, 192 (2005), pp. 36S-43S
[47.]
J.E. Bines.
Rotavirus vaccines and intussusception risk.
Curr Opin Gastroenterol, 21 (2005), pp. 20-25
[48.]
J.E. Bines.
Intussusception and rotavirus vaccines.
Vaccine, 24 (2006), pp. 3772-3776
[49.]
J.E. Bines, N.T. Liem, F.A. Justice, et al.
Risk factors for intussusception in infants in Vietnam and Australia: adenovirus implicated, but not rotavirus.
J Pediatr, 149 (2006), pp. 452-460
[50.]
M. Lynch, W.J. Shieh, J.S. Bresee, et al.
Intussusception after administration of the rhesus tetravalent rotavirus vaccine (Rotashield): the search for a pathogenic mechanism.
Pediatrics, 117 (2006), pp. 827e-832e
[51.]
L. Simonsen, R.J. Taylor, A.Z. Kapikian.
Rotavirus vaccines.
N Engl J Med, 354 (2006), pp. 1747-1751
[52.]
D.I. Bernstein, D.A. Sack, E. Rothstein, K. Reisinger, V.E. Smith, D. O'Sullivan, et al.
Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trial.
Lancet, 354 (1999), pp. 287-290
[53.]
T. Vesikari, A. Karvonen, L. Puustinen, S.Q. Zeng, E.D. Szakal, A. Delem, et al.
Efficacy of RIX4414 live attenuated human rotavirus vaccine in finnish infants.
Pediatr Infect Dis J, 23 (2004), pp. 937-943
[54.]
B. Salinas, I. Pérez-Schael, A.C. Lindares, G.M. Ruiz Palacios, L. Guerrero, J.P. Yarzabal, et al.
Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414. A randomized placebo-controlled trial in Latin America infants.
Pediatr Infect Dis J, 24 (2005), pp. 807-816
[55.]
G.M. Ruiz-Palacios, I. Pérez-Schael, R. Velázquez, H. Abate, T. Breuer, S. Costa, et al.
Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis.
N Engl J Med, 354 (2006), pp. 11-22
[56.]
T. Ruuska, T. Vesikari.
Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes.
Scand J Infect Dis, 22 (1990), pp. 259-267
[57.]
Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor JC, Cohen S, et al. Human rotavirus vaccine RotarixTM (Rix4414) is highly efficacious in Europe [abstract 475]. 24th ESPID. Basel: 3-5 de mayo de 2006; pág. 235
[58.]
Ficha Técnica Rotarix. EMEA 2007. Disponible en: http://www.emea.europa.eu/humandocs/PDFs/EPAR/rotarix/H-639-PI-es.pdf
[59.]
Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor JC, Cohen R, et al. RIX4414 (Rotarix™) is highly effective against severe RVGE caused by specific rotavirus types during the first two years of life. Abstract n.° 668. 45th Annual Meeting of the Infectious Diseases Society of America (IDSA). San Diego, California. October 2007.
[60.]
Tejedor JC, Díez Delgado J, Arístegui J, Mares J, Alzua J, De la Fuente E, et al. Rotarix® (Rix4414), an oral human rotavirus vaccine, is highly immunogenic when co-administered with a Neisseria meningitidis serogroup C vaccine (Meningitec®) in healthy infants from Spain [abstract 456]. 24th ESPID. Basel: 3-5 de mayo de 2006; pág 235.
[61.]
T. Vesikari, D.O. Matson, P. Dennehy, P. Van Damme, M. Santosham, Z. Rodríguez, et al.
Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine.
N Engl J Med, 354 (2006), pp. 23-33
[62.]
H.F. Clark, F.E. Borian, L.M. Bell, K. Modesto, S. Plotkin.
Protective effect of WC3 vaccine against rotavirus diarrhea in infants during a predominantly serotype 1 rotavirus season.
J Infect Dis, 158 (1988), pp. 570-587
[63.]
Disease Control and Prevention (CDC).
Postmarketing monitoring of intussusception after RotaTeq™ vaccination: United States, February 1, 2006-February 15, 2007.
MMWR, 56 (2007), pp. 218-222
[64.]
Vesikari T, Van Damme P, Gothefors L, Goveia M, Dallas M, Itzler R, Heaton P. Efficacy of Rotateq® to reduce any severity and severe rotavirus disease in Europe. Abstract to 25th International Congress of Pediatrics (ICP). Athens, Greece. August 30, 2007.
[65.]
Ficha Técnica RotaTeq. EMEA 2007. Disponible en: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Rotateq/H-669-PI-es.pdf
[66.]
Z.M. Rodríguez, M.G. Goveia, J.E. Stek, M.J. Dallas, J.W. Boslego, M.J. DiNubile, et al.
Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States.
Pediatr Infect Dis J, 26 (2007), pp. 221-227
Copyright © 2008. Elsevier España S.L.. Todos los derechos reservados
